The Royal Pharmaceutical Society (RPS) recorded a net loss of Elm in 2014 following a rise in costs attributed to investment in staff and product development. Overall expenditure by the RPS in the calendar year 2014 rose by almost ￡2m while income increased by only ￡913,000. The 2014 loss was higher than the budgeted deficit of ￡849,000.
展开▼
